Evaluation and Treatment of Fetal Bradycardia

Children's Mercy Fetal Cardiology Education Series: February 8, 2022

Amanda McIntosh, MD

Pediatric Cardiology, Ward Family Heart Center Children's Mercy Hospitals and Clinics, Kansas City, MO Pediatric and Fetal Echocardiography Clinical Assistant Professor of Pediatrics, University of Missouri-Kansas City Education Assistant Professor of Pediatrics, University of Kansas







Disclosures

• No relevant disclosures





Overview

- Fetal rhythm background and diagnosis review
- Fetal bradycardia differential diagnosis
 - Sinus bradycardia
 - Blocked atrial bigeminy
 - Long QT Syndrome
 - Atrioventricular (AV) Block
- Prognosis
- Surveillance
- Treatment and Delivery





Fetal Rhythm Review

- Heart begins to beat at 22 days of gestation
- By 6 weeks post-conception, AV synchrony can be demonstrated
- Normal fetal heart rate is age-dependent
 - 6 weeks 100 bpm
 - 9 weeks 170 bpm
 - 14 weeks 150 bpm
 - 20 weeks to term 140 bpm
- Beat-to-beat variation 5-15 bpm
- Generally, 120-160bpm considered "normal"
- Intrapartum definition of bradycardia is <110bpm





Fetal Echo Arrhythmia Diagnosis Review







The normal cardiac conduction system







The normal cardiac conduction system



interval

Pulmonary.vein

- This slowing corresponds to the PR or AV or mechanical PR interval
- If the AV node is abnormal, impulses are delayed (1° AV block), intermittently or not at all conducted (2° and 3° AV block

LOVE WILL.

...or any systemic vein and artery



The normal cardiac conduction system



 The impulses are conducted down the HIS purkinjie system and the bundle branches.



Image from Pediatric Heart Speciali<mark>st</mark>s Dallas Texas Ventricular contractions on simultaneous atrial and ventricular m-

Great vessel pulsed

mode

Doppler

Health

S-wave of systemic or pulmonary vein





Fetal Bradycardia: Background

- FHR decreases during gestation from 175bpm at 19 weeks to 138 bpm at 40 weeks
- Definition: HR >3rd percentile for gestational age
- Incidence of fetal arrhythmias in general is 1-2% of all pregnancies and account for 10-20% of referrals to fetal cardiologists
- Fetal Bradycardia is rare, only ~5% of all arrhythmia referrals
- Congenital complete heart block (CCHB) can be fatal in utero





Fetal Bradycardias by Type

- Sinus Bradycardia
- Blocked atrial bigeminy
- Long QT Syndrome
- AV block
 - 1st degree Heart block
 - 2nd degree heart block
 - Mobitz Type I
 - Mobitz Type II
 - Complete Heart block





Fetal Echo Bradycardia Evaluation

- Assess fetal well-being
- Assess anatomy
- Diagnose rhythm





Fetal Arrhythmia Evaluation: Fetal Well Being

Assess Anatomy and Degree of Heart Failure









Cardiovascular Profile Score







Fetal Bradycardia and Associated Lesions

Structural defect

- Heterotaxy
- **'Sinus"** (ectopic multiple or absent sinus node)

Normal Structure

- Chromosome/CNS abnormality
- IUGR/Maternal medication/Distress
- LQTS
- Familial SB/"Sinus node "dysfunctior
- Anti-SSA antibodies

Junctional

LOVE WILL.

Anti-SSA antibodies

- L-transposition
- AV Block . Left atrial isomerism
 - Situs solitus and AV canal defect
- Any defect atrial bigeminy

- LQTS
- Anti-SSA antibodies
- No association



Fetal Bradycardia Rhythm Diagnosis

- Step 1: Determine Rate and Regularity
- Step 2: Determine Number of As and Vs and AV relationship
- Step 3: Measure Mechanical PR interval





Fetal Bradycardias: Regular or Irregular?

Regular:

- Sinus Bradycardia
- Complete Heart block
- Long QT Syndrome
- Blocked atrial bigeminy
- 2:1 Mobitz Type II heart block

Irregular:

- Blocked atrial ectopic beats
- Intermittent Mobitz Type II Heart block
- Mobitz Type I Heart block
- Sinus node dysfunction with ventricular ectopic beats





Assessment of Fetal Bradycardia by AV relationship





LOVE WILL.

Mechanical PR Interval









AV interval >150ms is abnormal,

Mechanical PR interval overestimates the actual fetal AV interval





Sinus Bradycardia

- Regular 1:1 AV conduction with rate <110 bpm
- Uncommon, generally well-tolerated in absence of structural or functional defect
- Rare Genetic abnormalities
 - Loss of function mutations in cardiac sodium channel SCN51
 - Mutation in pacemaker HCN4 ion channel
- Damage to normal sinus node
 - Viral or bacterial infection
 - Maternal SSA antibodies





Sinus Bradycardia work-up

- Ensure no extracardiac reasons for bradycardia
- Check maternal anti-SSA antibodies
- Parental ECG and detailed family history to rule out LQTS
 - Focus on syncope, sudden death, SIDS, drownings
- Consider fetal MCG





Sinus Bradycardia

- Regular
- 1:1 AV conduction
- Normal AV interval







LOVE WILL.

Fetal Bradycardia: Long QT Syndrome







Long QT Syndrome

- Genetic abnormality of the sodium and potassium channels regulating cardiac repolarization occurring in 1/2000 subjects
- •> 600 mutations in 12 susceptibility genes have been found
- •1/3 are novel mutations
- •25% are genetically elusive
- Typically presents in adolescence or young adulthood with syncope, sudden death or cardiac arrest BUT
- 10% of ostensibly normal IUFD and SIDS are secondary to LQTS mutations
- Only 1/7000 identified before birth





Fetal Long QT Syndrome

- "Mild" regular 1:1 AV conduction bradycardia with Fetal HR <3rd percentile for GA but >110bpm may be only clue
- Signature fetal rhythm abnormalities:
 - 2nd degree AV block
 - Torsades de Pointe
 - However, only occur in ~25% of fetuses
 - · Cannot be accurately diagnosed via fetal echo
- Parental ECGs are imperative





Fetal Long QT Syndrome Diagnosis

- Must have high index of suspicion:
 - Structurally normal heart with any of the below:
 - Low baseline FHR 110-130bpm
 - Sinus Bradycardia <110bpm
 - Ventricular arrhythmias
 - 2nd degree heart block
 - Signs of unexplained heart failure
- Fetal MCG can make diagnosis





Normal fetal heart rate curves by GA



Jason L. Mitchell. Circulation. Fetal Heart Rate Predictors of Long QT Syndrome, Volume: 126, Issue: 23, Pages: 2688-2695, DOI: (10.1161/CIRCULATIONAHA.112. 114132)



LOVE WILL.

Long QT Syndrome and Sinus "Bradycardia"



Jason L. Mitchell. Circulation. Fetal Heart Rate Predictors of Long QT Syndrome, Volume: 126, Issue: 23, Pages: 2688-2695, DOI: (10.1161/CIRCULATIONAHA.112.114132) © 2012 American Heart Association, Inc.





Long QT Syndrome and heart "block"

- QT interval is so long that atrial electrical impulse occurs during refractory period of ventricle
- The ventricle is not "ready" to receive another impulse, thus the atrial impulse does not result in ventricular contractions





Long QT Syndrome Signature Arrhythmias



Ventricular Tachycardia 10-











"FHR a little lower than what I see at this GA"



Infant found to have KCNQ1 mutation G314D





Long QT Syndrome: Prognosis and Treatment

- Frequent fetal echo evaluation surveilling for fetal well-being and arrhythmias
- Complete post-natal work-up required
- LQTS accounts for >10% of SIDS
 - Prenatal suspicion can guide postnatal evaluation and prevention of SIDS
- No specific in utero treatment unless ventricular arrhythmias seen





Blocked atrial bigeminy

- Regular ventricular rate, A>V, irregular A-A interval
- FHR often <100bpm
- Most common cause of irregular heart rhythm
- Can be associated with slow or normal FHR
- Early atrial beat comes in before ventricle is ready to receive another beat, meaning, ectopic beat is blocked
- No hemodynamic significance, but MUST be distinguished from pathologic 2:1 AV block
 - The Great Pretender
- Accurate measure of A-A interval is key





Fetal Irregular Rhythm: Premature Atrial Contractions



Blocked atrial bigeminy

Distance Between a-a' is less than the distance from a' - a







Irregular Rhythm: Blocked atrial ectopy versus pathologic AV block



Primary bradycardia: keys and pitfalls in diagnosis J.S. Carvalho, USOG 2014





Regular Rhythm: Blocked atrial ectopy v. pathologic AV block













Management of Atrial and Ventricular Ectopy

A	N/ . · · / P .
Atrial Ectopy	ventricular Ectopy
1. Confirm normal structure	1. Confirm normal structure
2. Weekly FHR auscultation	2. Consider infectious etiology
 Monthly fetal echo if ectopy persists 	3. R/o Tumors and diverticulum, consider LQTS
4. Postnatal ECG if ectopy persists	4. Weekly FHR auscultation; consider home Doppler
	5. Monthly fetal echo if ectopy persists
	6. Postnatal ECG





Fetal Bradycardia: AV block

- 1st degree AV block
 - Prolonged mechanical PR interval >170ms
 - A=V
 - regular
- 2nd degree AV block
 - Mobitz Type I
 - Mobitz Type II
 - A>V, but A-V relationship exists
 - Irregular or regular
- 3rd degree (complete) AV block
 - A>Ŭ
 - No A/V relationship
 - Regular
 - FHR ~50-90 bpm





Fetal Bradyarrhythmia: Mobitz Mobitz Type I 2nd degree block



Mitral Inflow/aortic outflow Doppler SSA+

Atrium/ventricle M-mode SSA+





Fetal Irregular Rhythm: Intermittent Mobitz II AV block



Mitral Inflow/aortic outflow Doppler SSA+







Complete 3rd degree Heart Block





LOVE WILL.

Complete Heart Block and Cardiomyopathy







Fetal Bradycardia Diagnosis Flowchart Review



LOVE WILL.

Fetal Bradycardia: AV Block

- Inflammation and/or scarring (fibrosis) of the AV node secondary to maternal autoantibodies or a structurally abnormal AV node prevents electric signals from the atria from reaching the ventricles
- Almost all inflammatory or scarring AVB develops in the second trimester of pregnancy (18-26 weeks of gestation), but placental transfer of offending maternal autoantibodies can occur as early as 11 weeks gestation
- Heart block secondary to complex structural disease can occur as early as 13 weeks





AV block can be associated with:

- Structurally and genetically normal heart
 - SSA antibody mediated disease
 - Maternal metabolic disease or medications
 - Viral infections
- Structurally and genetically abnormal heart
 - Long QT Syndrome
 - Other channelopathies
- Congenital heart disease
 - Heterotaxy (Left atrial isomerism)
 - Congenitally corrected transposition of the great arteries





Fetal AV block secondary to SSA antibodies

- Fetal AVB secondary to anti-Ro/SSA antibodies "neonatal lupus" spectrum
- Fetal AVB occurs in 2% of pregnant women who carry anti-Ro/SSA antibodies
- 20% in utero mortality rate for immune mediated congenital heart block
- 2/3 of fetuses who survive require pacemaker implantation after birth, most within first 10 days
 - Prognosis is excellent if ventricular function is preserved after pacemaker implantation
 - 10% will develop cardiomyopathy in first year of life
 - Antibodies can also affect myocardium





What are SSA Antibodies and who has them?

- Autoantibodies which react with a protein in all cells and can damage fetal AV node and myocardium
- Some individuals with anti-Ro/SSA antibodies have known autoimmune diseases such as lupus or Sjogren's syndrome, but most (~2/3) do not have identified autoimmune disease at time of CCHB diagnosis
 - Currently no universal screening for SSA antibodies in pregnant women
- Risk to develop CHB in SSA positive pregnancies is slightly higher in those with active disease
- Risk of heart block in subsequent pregnancies after previously affected child is 9x higher, i.e. ~18% risk





Presentation and Progression of SSAantibody mediated Heart block

- Goal is early identification and treatment
 - Currently face challenges in both identifying and knowing which fetuses would benefit from treat
- Complete (3rd degree heart block) is likely irreversible and is often initial presenting rhythm
- Early (first or 2nd degree heart block) is potentially treatable BUT
- Progression from 1st/2nd degree heart block to Complete heart block can be rapid (<24-48 hours)
 - Weekly or biweekly monitoring may be insufficient to detect this period and treat to prevent CAVB
- In addition, some cases of fetal first degree AVB do not progress to higher grade block during pregnancy or after delivery





Fetal Bradyarrhythmia: Presentation of SSA-mediated cardiac disease



96% Signature rhythm of AV Block

Izmirly PM. Circulation 2011





Surveillance of SSA+ Positive Mother

Congenital Heart Disease

Utility of Cardiac Monito Risk for Congenital The PR Interval and Dexame (PRIDE) Prospectiv

Deborah M. Friedman, MD; Mimi Y. Kim, ScD; Josh Colin K.L. Phoon, MPhil, MD; Julie S. Glick for the PRIDE Invest



JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

VOL. 72, NO. 16, 2018

Home Monitoring for Fetal Heart Rhythm During Anti-Ro Pregnancies

Bettina F. Cuneo, MD,^a Sven-Erik Sonesson, MD,^b Stephanie Levasseur, MD,^c Anita J. Moon-Grady, MD,^d Anita Krishnan, MD,^e Mary T. Donofrio, MD,^e Marie-Josee Raboisson, MD,^f Lisa K. Hornberger, MD,^g Peter Van Eerden, MD,^h Elena Sinkovskaya, MD,ⁱ Alfred Abuhamad, MD,ⁱ Bhawna Arya, MD,^j Anita Szwast, MD,^k Helena Gardiner, MD,¹ Katherine Jacobs, MD,^m Grace Freire, MD,ⁿ Lisa Howley, MD,^a Aimee Lam, BS,^a

NIH U.S. National Library of Medicine

ClinicalTrials.gov

Find Studies
About Studies
Submit Studies
Resources
About Site
PRS Login

Home > Search Results > Study Record Detail

Save this study

Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)





Surveillance of SSA+ Positive Mother

- PRIDE (PR interval and Dexamethasone Evaluation) study-2010
- 95 pregnancies evaluated
- Weekly fetal echoes performed from 16-26 weeks, bi-weekly 26-34 weeks
- PR >150ms considered prolonged, i.e. 1st degree block
- 3 fetuses developed 3rd degree AV block at 19-23 weeks GA, none had preceding abnormal PR interval on screening fetal echoes within 1-2 weeks prior
- 2 fetuses with PR >150ms detected prior to 22 weeks, reversed with treatment with dexamethasone





- 315 SSA+ mothers from 16 centers observed prospectively
- Ambulatory fetal heart monitoring
 - Handheld <u>home Doppler</u> operated by mothers, concerning rhythm sent to fetal cardiologist
 - 273 (87%) completed monitoring protocol, maternal stress/anxiety evaluated and in general found to be empowering to mother
- Monitoring Protocol:
 - Baseline echocardiogram at 16-19 weeks
 - Surveillance:
 - Fetal echoes every week or every other week up to 26
 weeks
 - Twice a day FHRM
 - Diagnostic fetal echo if concerns about FHRM
 - Routine OB care after 26 weeks



Cuneo et. al Surveillance for Fetal AV Block by Home Monitoring *JACC 2018*





- 3 fetuses developed AVB between 18-22 weeks gestation
 - All detected by FHRM and confirmed by fetal echo
 - All treated with dexamethasone and IVIG after detection
 - All with normal fetal echoes for both rhythm and function 2-4 days preceding FHRM
 - All fetal echoes performed after abnormal FHRM demonstrated EFE or AVVI in addition to rhythm abnormality that was not present on preceding echo

Cuneo et. al Surveillance for Fetal AV Block by Home Monitoring *JACC 2018*





- Fetus #1, irregular rhythm on FHRM
 - Fetal echo performed same day with intermittent 2nd degree AV block and 1st degree AV block
 - restored to sinus rhythm
- 2 other fetuses with 3rd degree AV block at time of diagnostic fetal echo did not reverse with treatment
 - Fetus #2 with detected bradycardia on FHRM, fetal echo 8 hours later
 - Fetus #3, irregular rhythm on FHRM, waited 12 hours before calling cardiologist after repeat HRM demonstrated FHR <100bpm, fetal echo 8 hours later

Cuneo et. al Surveillance for Fetal AV Block by Home Monitoring *JACC 2018*



LOVE WILL.



- No instances of first degree AVB progressing to 2nd-degree AVB
- No missed cases of AVB
- 50% false positive rate (11/21)
 - Other non AVB abnormalities found were PACs and frequent sinus pauses
 - Functional fetal echo abnormalities only found on AVB patients





Treatment of Heart block

- No standardized medical therapy exists
 - Still do not know who benefits from treatment the most and at what dosages
- Goals of treatment are 2-fold:
 - Prevent progression to higher-degree AV block
 - Decrease risk for development of fetal distress and progression to hydrops secondary to myocardial involvement





Treatment of Heart block

- Oral Corticosteroids
 - reduced immune-mediated AV-node and myocardial damage
 - Highest benefit during emergent CCHB (first-or second-degree AV block) or those with fetal hydrops
 - Maternal and fetal deleterious side effects occur, so dose is often decreased as pregnancy progresses
- Beta-adrenergic therapy
 - Generally used in patients with FHR <55bpm and signs of fetal cardiac impairment (hydrops, AVVR)-can increase FHR by 10-15%
 - Data mixed whether this improves outcomes
- IVIG
 - Reduced circulating maternal antibodies to reduce placental transmission
 - Mixed results in the literature, not used for first degree AV block, reserved for 2nd degree AV block or those with concerns for ongoing myocardial inflammation
 - Requires inpatient admission
- Fetal Pacing
 - Experimental, potentially coming in future, not realist option now
 - Very high risk, issues with placement and lead dislodgement





Post-Natal Management Complete Heart Block

- For non-CHD immune mediated CHB, generally recommend delivery at 37 weeks
 - C-section often recommended given inability to monitor for fetal distress during labor
- For high-risk infants with hydrops and/or ventricular dysfunction, must balance risk of demise with risks related to prematurity:
 - Technical aspects of pacing in small infants
 - Possible need for cardiac transplantation for cardiomyopathic infants
 - If non-immune and associated with CHD, must consider needed intervention and ductal dependency and lung prematurity





STOP BIOQ Trial

- Surveillance and Treatment tO Prevent Fetal AV Block Likely to Occur Quickly
- Over thirty participating sites across the US and Canada
- A prospective observational trial with 3 steps:
 - Screening for high titer antibodies
 - Surveillance by FHRM 3X daily and weekly or biweekly echo
 - Treatment of 2° AVB identified by FHRM and confirmed by echo
 - 1st degree AVB (PR>170ms): Dexamethasone 8mg daily x 10 days, then 4mg/daily through 28 weeks, then 3mg through 29 weeks, then 2mg daily through delivery
 - 2nd degree AVB: IVIG 1g/kg within 12 hours of detection by home monitoring and 6 hours of confirmation by fetal echo
- Primary outcome: percentage of 2nd degree AVB patients with normal rhythm at delivery
- Secondary outcomes: percentage of 1st degree AVB patients with normal rhythm at delivery, extra-nodal cardiac disease, rhythm at one year of age





Prevention of SSA Heart Blo

HHS Public Access Author manuscript *J Am Coll Cardiol*, Author manuscript; available in PMC 2021 July 21.

Published in final edited form as: J Am Coll Cardiol. 2020 July 21; 76(3): 292–302. doi:10.1016/j.jacc.2020.05.045.

Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers

Peter Izmirly, MD^{a,*}, Mimi Kim, ScD^b, Deborah M. Friedman, MD^c, Nathalie Costedoat-Chalumeau, MD, PhD^d, Robert Clancy, PhD^a, Joshua A. Copel, MD^e, Colin K. L. Phoon, MPhil, MD^a, Bettina F. Cuneo, MD^f, Rebecca Cohen, BA^a, Kimberly Robins, MS^a, Mala Masson, BA^a, Benjamin J. Wainwright, BA^a, Noel Zahr, PharmD, PhD^g, Amit Saxena, MD^a, Jill P. Buyon, MD^a

Allow Verk Liniversity Cohool of Madiaina, New York, NV 110

- Prospective study of pregnant mothers with previous pregnancy complicated by immune-mediated heart block
- Hydroxychloroquine 400mg daily given prior to completion of 10
 weeks GA throughout pregnancy
- Recurrence rate decreased to 7.4% from historical rate of ~18-20%





Recommendations for SSA-Positive Pregnancy Monitoring

- Fetal Cardiology Evaluation starting at 16 weeks
- Weekly evaluation until 28 weeks
 - At minimum, fetal echoes every 2 weeks
 - Evaluation should include BPPS and/or CVS (if heart rate concerns)
 - Consider 2-3x daily ambulatory FHRM for selected patients
- In the absence of AVB, fetal echoes should continue every 2-4 weeks after 28 weeks until delivery due to risk of late myocardial complications





Recommendations for SSA-Positive Pregnancy Treatment

- Consider hydroxychloroquine initiation prior to 10 weeks gestation
- Consider dexamethasone for 1st or 2nd degree AVB +/- IVIG
- Consider sympathomimetics for Ventricular rate <55bpm or signs of hydrops
- Consider digoxin for cardiomyopathy
- No treatment recommended for sinus bradycardia, blocked atrial bigeminy
- Specialized delivery planning required for FHR <70bpm, cardiac dysfunction, or hydrops
- Hopefully more evidence coming with the STOP-Bloq trial





CCHB with structural heart disease

- L-Transposition of the great arteries
- Heterotaxy-polysplenia syndrome (left atrial isomerism)
- Less commonly in AVSD, other forms of CHD
- Can be associated with significant in-utero mortality, ranging from 5% (L-TGA) to 75-90% (left atrial isomerism)
 - Risk factors for mortality:
 - Hydrops
 - Ventricular rate <55bpm
 - Decreased LVEF or dilation
 - Presence of endocardial elastofibrosis
 - Significant AVV regurgitation





Congenitally Corrected Transposition of the Great Arteries











CHB with Heterotaxy Syndrome







CCHB with structural heart disease

- Still largely untreatable in-utero
- Goals are surveillance for fetal distress
- Consideration of beta-agonists +/- digoxin for signs of heart failure and/or hydrops
- Specialized delivery planning for FHR <55bpm and significant cardiomyopathy
 - Consideration of C-Section
 - Possible prostaglandin
 - Preparation for emergent temporary post-natal pacing
 - Often requires cardiology, CVOR and EP team on standby





Thank You

• Questions?





Acknowledgements

- Bettina Cuneo, MD, pioneer of fetal heart block and my mentor during training
- Children's Mercy Fetal Health Center sonographers, nurses, and my fetal cardiology and maternal fetal medicine physician colleagues
- The families who allow us to care for them



